{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:15:15Z","timestamp":1764180915153,"version":"3.46.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04496-8","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:00:03Z","timestamp":1763982003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study"],"prefix":"10.1186","volume":"25","author":[{"given":"Yasar","family":"Torres-Yaghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambros","family":"Chrones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Brunson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"2","key":"4496_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2.","journal-title":"Lancet Neurol"},{"issue":"3","key":"4496_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14(3):176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9.","journal-title":"Cell Death Dis"},{"issue":"1","key":"4496_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of synucleinopathies. Mol Neurodegener. 2021;16(1):83. https:\/\/doi.org\/10.1186\/s13024-021-00501-z.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"4496_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","volume":"19","author":"JP Taylor","year":"2020","unstructured":"Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of lewy body dementia. Lancet Neurol. 2020;19(2):157\u201369. https:\/\/doi.org\/10.1016\/S1474-4422(19)30153-X.","journal-title":"Lancet Neurol"},{"issue":"4","key":"4496_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2014","unstructured":"Vann Jones SA, O\u2019Brien JT. The prevalence and incidence of dementia with lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44(4):673\u201383. https:\/\/doi.org\/10.1017\/S0033291713000494.","journal-title":"Psychol Med"},{"issue":"4","key":"4496_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","volume":"13","author":"D Aarsland","year":"2017","unstructured":"Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217\u201331. https:\/\/doi.org\/10.1038\/nrneurol.2017.27.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"4496_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/j.1582-4934.2011.01311.x","volume":"16","author":"KA Jellinger","year":"2012","unstructured":"Jellinger KA. Cerebral correlates of psychotic syndromes in neurodegenerative diseases. J Cell Mol Med. 2012;16(5):995\u20131012. https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01311.x.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"4496_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/jad-231363","volume":"99","author":"C Cressot","year":"2024","unstructured":"Cressot C, Vrillon A, Lilamand M, Francisque H, M\u00e9auzoone A, Hourregue C, et al. Psychosis in neurodegenerative dementias: A systematic comparative review. J Alzheimers Dis. 2024;99(1):85\u201399. https:\/\/doi.org\/10.3233\/jad-231363.","journal-title":"J Alzheimers Dis"},{"key":"4496_CR9","unstructured":"Acadia Pharmaceuticals Inc. NUPLAZID\u00ae (pimavanserin) Prescribing Information Full Prescribing Information. 2025."},{"key":"4496_CR10","doi-asserted-by":"publisher","first-page":"105951","DOI":"10.1016\/j.parkreldis.2023.105951","volume":"119","author":"D Weintraub","year":"2024","unstructured":"Weintraub D, Espay AJ, Sharma VD, Tariot PN, Abler V, Pathak S, Stankovic S. Pimavanserin for psychosis in parkinson\u2019s disease dementia: subgroup analysis of the HARMONY trial. Parkinsonism Relat Disord. 2024;119:105951. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105951.","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"4496_CR11","first-page":"368","volume":"42","author":"MP Cruz","year":"2017","unstructured":"Cruz MP. Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with parkinson\u2019s disease. P T. 2017;42(6):368\u201371.","journal-title":"P T"},{"issue":"10","key":"4496_CR12","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","volume":"39","author":"U Hacksell","year":"2014","unstructured":"Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H. On the discovery and development of pimavanserin: a novel drug candidate for parkinson\u2019s psychosis. Neurochem Res. 2014;39(10):2008\u201317. https:\/\/doi.org\/10.1007\/s11064-014-1293-3.","journal-title":"Neurochem Res"},{"issue":"2","key":"4496_CR13","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1124\/jpet.105.097006","volume":"317","author":"KE Vanover","year":"2006","unstructured":"Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2019-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006;317(2):910\u20138. https:\/\/doi.org\/10.1124\/jpet.105.097006.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"4496_CR14","doi-asserted-by":"publisher","first-page":"Cd013304","DOI":"10.1002\/14651858.CD013304.pub2","volume":"12","author":"V M\u00fchlbauer","year":"2021","unstructured":"M\u00fchlbauer V, M\u00f6hler R, Dichter MN, Zuidema SU, K\u00f6pke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with alzheimer\u2019s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12(12):Cd013304. https:\/\/doi.org\/10.1002\/14651858.CD013304.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"4496_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/14740338.2022.2069240","volume":"21","author":"SH Isaacson","year":"2022","unstructured":"Isaacson SH, Citrome L. Hallucinations and delusions associated with parkinson\u2019s disease psychosis: safety of current treatments and future directions. Expert Opin Drug Saf. 2022;21(7):873\u20139. https:\/\/doi.org\/10.1080\/14740338.2022.2069240.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"4496_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4088\/JCP.v66n0514","volume":"66","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Perry R, Larsen JP, McKeith I, O\u2019Brien J, Perry EK, et al. Neuroleptic sensitivity in parkinson\u2019s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"4496_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2034634","volume":"385","author":"PN Tariot","year":"2021","unstructured":"Tariot PN, Cummings JL, Soto-Martin ME, Ballard C, Erten-Lyons D, Sultzer DL, et al. Trial of Pimavanserin in dementia-related psychosis. N Engl J Med. 2021;385(4):309\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2034634.","journal-title":"N Engl J Med"},{"key":"4496_CR18","volume-title":"Scale for the assessment of positive symptoms (SAPS). Iowa City","author":"N Andreasen","year":"1984","unstructured":"Andreasen N. Scale for the assessment of positive symptoms (SAPS). Iowa City. IA: University of Iowa; 1984."},{"issue":"7","key":"4496_CR19","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"issue":"12","key":"4496_CR20","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O\u2019Brien JT, Feldman H, et al. Diagnosis and management of dementia with lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863\u201372. https:\/\/doi.org\/10.1212\/01.wnl.0000187889.17253.b1.","journal-title":"Neurology"},{"issue":"12","key":"4496_CR21","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with parkinson\u2019s disease. Mov Disord. 2007;22(12):1689\u2013707. https:\/\/doi.org\/10.1002\/mds.21507.","journal-title":"Mov Disord"},{"key":"4496_CR22","doi-asserted-by":"publisher","unstructured":"Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res. 2005;76(2\u20133). https:\/\/doi.org\/10.1016\/j.schres.2005.02.013. 247\u2009\u2013\u200965.","DOI":"10.1016\/j.schres.2005.02.013"},{"issue":"3","key":"4496_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"issue":"9916","key":"4496_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(13)62106-6.","journal-title":"Lancet"},{"issue":"1","key":"4496_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","volume":"16","author":"KA Jellinger","year":"2018","unstructured":"Jellinger KA, Korczyn AD. Are dementia with lewy bodies and parkinson\u2019s disease dementia the same disease? BMC Med. 2018;16(1):34. https:\/\/doi.org\/10.1186\/s12916-018-1016-8.","journal-title":"BMC Med"},{"issue":"1","key":"4496_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.19052","volume":"13","author":"M Yamada","year":"2020","unstructured":"Yamada M, Komatsu J, Nakamura K, Sakai K, Samuraki-Yokohama M, Nakajima K, Yoshita M. Diagnostic criteria for dementia with lewy bodies: updates and future directions. J Mov Disord. 2020;13(1):1\u201310. https:\/\/doi.org\/10.14802\/jmd.19052.","journal-title":"J Mov Disord"},{"issue":"15","key":"4496_CR27","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons CH, Levine T, Adler C, Bellaire B, Wang N, Stohl J, et al. Skin biopsy detection of phosphorylated alpha-synuclein in patients with synucleinopathies. JAMA. 2024;331(15):1298\u2013306. https:\/\/doi.org\/10.1001\/jama.2024.0792.","journal-title":"JAMA"},{"issue":"4","key":"4496_CR28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","volume":"89","author":"G Rizzo","year":"2018","unstructured":"Rizzo G, Arcuti S, Copetti M, Alessandria M, Savica R, Fontana A, et al. Accuracy of clinical diagnosis of dementia with lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(4):358\u201366.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04496-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04496-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04496-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:13:19Z","timestamp":1764180799000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04496-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4496"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04496-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to the initiation of the HARMONY trial, the protocol was approved by institutional review boards (Advarra d\/b\/a Schulman Associates Institutional Review Board, Inc, IRB# 00000971), and all patients or authorized representatives provided written informed consent. The HARMONY trial was conducted in accordance with ethical principles of Good Clinical Practice derived from the Declaration of Helsinki in addition to other applicable and local regulatory requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"YT-Y\n                      is a speaker and consultant for Abbott, AbbVie, Acadia, Acorda, Amneal, Kyowa Kirin, Sunovion, and Teva.\n                      LC\n                      ,\n                      VA\n                      , and\n                      GB\n                      are employees of Acadia Pharmaceuticals Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"479"}}